KR101283416B1 - Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법 - Google Patents

Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법 Download PDF

Info

Publication number
KR101283416B1
KR101283416B1 KR1020127016911A KR20127016911A KR101283416B1 KR 101283416 B1 KR101283416 B1 KR 101283416B1 KR 1020127016911 A KR1020127016911 A KR 1020127016911A KR 20127016911 A KR20127016911 A KR 20127016911A KR 101283416 B1 KR101283416 B1 KR 101283416B1
Authority
KR
South Korea
Prior art keywords
ampk
stroke
ischemic
pampk
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127016911A
Other languages
English (en)
Korean (ko)
Other versions
KR20120078756A (ko
Inventor
루이스 디. 매클러
홍 리
질 맥패든
가브리엘 브이. 로네트
Original Assignee
더 존스 홉킨스 유니버시티
파스젠, 엘엘씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티, 파스젠, 엘엘씨. filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20120078756A publication Critical patent/KR20120078756A/ko
Application granted granted Critical
Publication of KR101283416B1 publication Critical patent/KR101283416B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020127016911A 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법 Expired - Fee Related KR101283416B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55600004P 2004-03-24 2004-03-24
US60/556,000 2004-03-24
PCT/US2005/009797 WO2005092068A2 (en) 2004-03-24 2005-03-23 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067022076A Division KR20070085093A (ko) 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법

Publications (2)

Publication Number Publication Date
KR20120078756A KR20120078756A (ko) 2012-07-10
KR101283416B1 true KR101283416B1 (ko) 2013-07-08

Family

ID=35056772

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127016911A Expired - Fee Related KR101283416B1 (ko) 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법
KR1020067022076A Ceased KR20070085093A (ko) 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067022076A Ceased KR20070085093A (ko) 2004-03-24 2005-03-23 Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법

Country Status (11)

Country Link
US (1) US8293791B2 (enExample)
EP (1) EP1734973A4 (enExample)
JP (1) JP2008504228A (enExample)
KR (2) KR101283416B1 (enExample)
CN (1) CN101132802A (enExample)
AU (1) AU2005226731A1 (enExample)
BR (1) BRPI0509085A (enExample)
CA (1) CA2560843A1 (enExample)
IL (1) IL178242A0 (enExample)
MX (1) MXPA06010916A (enExample)
WO (1) WO2005092068A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504228A (ja) 2004-03-24 2008-02-14 ファスジェン・リミテッド・ライアビリティ・カンパニー Ａｍｐ活性化プロテインキナーゼの薬理学的阻害による新規神経保護方法
WO2014160989A2 (en) 2013-03-28 2014-10-02 The Trustees Of Columbia University In The City Of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
KR101152607B1 (ko) 2005-12-20 2012-06-05 에스케이케미칼주식회사 ６-[４-(２-피페리딘-1-일-에톡시)-페닐]-３-피리딘-４-일-피라졸로[１,５-ａ]피리미딘의 제조방법
CA2749884C (en) 2009-01-28 2018-01-23 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
KR101532211B1 (ko) * 2014-04-30 2015-06-30 세종대학교산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법
CN119868551A (zh) * 2024-11-28 2025-04-25 四川大学华西医院 F-box蛋白48的抑制剂的新用途和治疗缺血性脑血管病的药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
JP2008504228A (ja) 2004-03-24 2008-02-14 ファスジェン・リミテッド・ライアビリティ・カンパニー Ａｍｐ活性化プロテインキナーゼの薬理学的阻害による新規神経保護方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy

Also Published As

Publication number Publication date
IL178242A0 (en) 2007-03-08
CA2560843A1 (en) 2005-10-06
EP1734973A2 (en) 2006-12-27
EP1734973A4 (en) 2010-08-04
WO2005092068A3 (en) 2007-09-20
JP2008504228A (ja) 2008-02-14
KR20120078756A (ko) 2012-07-10
BRPI0509085A (pt) 2007-08-21
MXPA06010916A (es) 2007-07-25
CN101132802A (zh) 2008-02-27
AU2005226731A1 (en) 2005-10-06
KR20070085093A (ko) 2007-08-27
US20090137665A1 (en) 2009-05-28
US8293791B2 (en) 2012-10-23
WO2005092068A2 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
McCullough et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke
US6288089B1 (en) Use of kinase inhibitors for treating neurodegenerative diseases
US20100056604A1 (en) Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv
JP2006502976A (ja) 虚血再潅流を治療する方法および組成物
Mudalagiri et al. Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol‐3 kinase and ERK1/2 activation
JPH07505124A (ja) ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
US20100216710A1 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
TW200410672A (en) NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
Leeds et al. Neurotrophins protect against cytosine arabinoside-induced apoptosis of immature rat cerebellar neurons
Willaime-Morawek et al. IGF-I protects cortical neurons against ceramide-induced apoptosis via activation of the PI-3K/Akt and ERK pathways; is this protection independent of CREB and Bcl-2?
Tang et al. Expression of different isoforms of protein kinase C in the rat hippocampus after pilocarpine‐induced status epilepticus with special reference to CA1 area and the dentate gyrus
KR101283416B1 (ko) Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법
EP1093379B1 (en) Use of inhibitors of protein kinase c epsilon to treat pain
Zheng et al. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway
Peng et al. Puerarin attenuates lipopolysaccharide-induced myocardial injury via the 14-3-3γ/PKCε pathway activating adaptive autophagy
Mukhopadhyay et al. Role of MAPK/AP-1 signaling pathway in the protection of CEES-induced lung injury by antioxidant liposome
Abe et al. The phosphatidylinositol-3 kinase/Akt pathway mediates geranylgeranylacetone-induced neuroprotection against cerebral infarction in rats
AU2001259453A1 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
Ciocci Pardo et al. Myocardial and mitochondrial effects of the anhydrase carbonic inhibitor ethoxzolamide in ischemia‐reperfusion
Arbeláez et al. Cardioprotection of benzolamide in a regional ischemia model: Role of eNOS/NO
HK1118217A (en) Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
Ceolotto et al. Effect of protein kinase C and insulin on Na+/H+ exchange in red blood cells of essential hypertensives
Naito et al. Immunohistochemical localization of mitogen-activated protein kinase (MAPK) family and morphological changes in rat heart after ischemia-reperfusion injury
JP2002511876A (ja) 心臓におけるインシュリン耐性を治療し、プロテインキナーゼｂ（ｐｋｂ）活性を強化するための組成物における成長ホルモンの使用
Bsc et al. Neuronal injury in NCX3 knockout mice following permanent focal cerebral ischemia and in NCX3 knockout cortical neuronal cultures following oxygen-glucose deprivation and glutamate exposure

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20160703

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160703

St.27 status event code: N-4-6-H10-H13-oth-PC1903

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000